01 noviembre 2011

CIRCULATION. Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis

Matthew R. Reynolds, MD, MSc; Elizabeth A. Magnuson, ScD; Yang Lei, MSc; Martin B. Leon, MD; Craig R. Smith, MD; Lars G. Svensson, MD, PhD; John G. Webb, MD; Vasilis C. Babaliaros, MD; Bruce S. Bowers, MD; William F. Fearon, MD; Howard C. Herrmann, MD; Samir Kapadia, MD; Susheel K. Kodali, MD; Raj R. Makkar, MD; Augusto D. Pichard, MD; David J. Cohen, MD, MSc; for the Placement of Aortic Transcatheter Valves (PARTNER) Investigators

Background—Transcatheter aortic valve replacement (TAVR) has been shown to improve survival compared with standard therapy in patients with severe aortic stenosis who cannot have surgery. The effects of TAVR on health-related quality of life have not been reported from a controlled study. Circulation. 2011; 124: 1964-1972 Published online before print October 3, 2011, doi: 10.1161/​CIRCULATIONAHA.111.040022. Copyright © 2011 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

01 noviembre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents

Bimmer E. Claessen, MD, PhD; Pieter C. Smits, MD; Dean J. Kereiakes, MD; Helen Parise, ScD; Martin Fahy, MSc; Elvin Kedhi, MD; Patrick W. Serruys, MD, PhD; Alexandra J. Lansky, MD; Ecaterina Cristea, MD; Krishnankutty Sudhir, MD, PhD; Poornima Sood, MD; Charles A. Simonton, MD; Gregg. W. Stone, MD

Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. J Am Coll Cardiol Intv. 2011;4(11):1209-1215. doi:10.1016/j.jcin.2011.07.016. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 noviembre 1011

JACC CARDIOVASCULAR INTERVENTIONS. Valve-in-Valve Transcatheter Aortic Valve Implantation for Degenerated Bioprosthetic Heart Valves

Holger Eggebrecht, MD; Ulrich Schäfer, MD; Hendrik Treede, MD; Peter Boekstegers, MD; Jörg Babin-Ebell, MD; Markus Ferrari, MD; Helge Möllmann, MD; Helmut Baumgartner, MD; Thierry Carrel, MD; Philipp Kahlert, MD; Philipp Lange, MD; Thomas Walther, MD; Raimund Erbel, MD; Rajendra H. Mehta, MD, MS; Matthias Thielmann, MD

Objectives; We sought to analyze outcomes of patients with degenerated surgically implanted bioprosthetic heart valves undergoing valve-in-valve (viv) transcatheter aortic valve implantation (TAVI). J Am Coll Cardiol Intv. 2011;4(11):1218-1227. doi:10.1016/j.jcin.2011.07.015. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 noviembre 2011

CIRCULATION. Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction

Judith S. Hochman, MD; Harmony R. Reynolds, MD; Vladimír Džavík, MD; Christopher E. Buller, MD; Witold Ruzyllo, MD; Zygmunt P. Sadowski, MD; Aldo P. Maggioni, MD; Antonio C. Carvalho, MD; James M. Rankin, MD; Harvey D. White, MD; Suzanne Goldberg, RN, MSN; Sandra A. Forman, MA; Daniel B. Mark, MD, MPH; Gervasio A. Lamas, MD for the Occluded Artery Trial Investigators

Background—Despite observations suggesting a benefit for late opening of totally occluded infarct-related arteries after myocardial infarction, the Occluded Artery Trial (OAT) demonstrated no reduction in the composite of death, reinfarction, and class IV heart failure over a 2.9-year mean follow-up. Follow-up was extended to determine whether late trends would favor either treatment group. Circulation. 2011; 124: 2320-2328 Published online before print October 24, 2011, doi: 10.1161/​CIRCULATIONAHA.111.041749. Copyright © 2011 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

01 noviembre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Transcatheter Valve-in-Valve Implantation Using CoreValve Revalving System for Failed Surgical Aortic Bioprostheses

Francesco Bedogni, MD; Maria Luisa Laudisa, MD, PhD; Samuele Pizzocri, MD; Corrado Tamburino, MD; Gian Paolo Ussia, MD; Anna Sonia Petronio, MD; Massimo Napodano, MD; Angelo Ramondo, MD; Patrizia Presbitero, MD; Federica Ettori, MD; Gennaro Santoro, MD; Silvio Klugman, MD; Federico De Marco, MD; Nedy Brambilla, MD; Luca Testa, MD, PhD

Objectives: The purpose of this study was to evaluate the performance of CoreValve Revalving System (CRS) (Medtronic, Minneapolis, Minnesota) implantation in patients with failed aortic bioprostheses. J Am Coll Cardiol Intv. 2011;4(11):1228-1234. doi:10.1016/j.jcin.2011.10.002. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 noviembre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Aortic Annulus Diameter Determination by Multidetector Computed Tomography. Reproducibility, Applicability, and Implications for Transcatheter Aortic Valve Implantation

Ronen Gurvitch, MBBS; John G. Webb, MD; Ren Yuan, MD; Mark Johnson, MBBS; Cameron Hague, MD; Alexander B. Willson, MBBS; Stefan Toggweiler, MD; David A. Wood, MD; Jian Ye, MD; Robert Moss, MD; Christopher R. Thompson, MD; Stephan Achenbach, MD; James K. Min, MD; Troy M. LaBounty, MD; Ricardo Cury, MD; Jonathon Leipsic, MD

Objectives: This study sought to determine the most reproducible multidetector computed tomography (MDCT) measurements of the aortic annulus and to determine methods to improve the applicability of these measurements for transcatheter aortic valve implantation. J Am Coll Cardiol Intv. 2011;4(11):1235-1245. doi:10.1016/j.jcin.2011.07.014. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

01 noviembre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Successful Percutaneous Anterograde Transcatheter Valve-in-Valve Implantation in the Mitral Position

Matteo Montorfano, MD; Azeem Latib, MD; Alaide Chieffo, MD; Shahram Moshiri, MD; Annalisa Franco, MD; Antonio Grimaldi, MD; Ottavio Alfieri, MD; Antonio Colombo, MD

A 71-year-old man with rheumatic mitral stenosis underwent mitral valve replacement 12 years ago with a 27-mm Carpentier-Edwards bioprosthesis (Edwards Lifesciences, Inc., Irvine, California). He presented with biventricular failure due to severe prosthetic mitral stenosis (valve area 0.8 cm2, mean gradient 19 mm Hg), despite palliative valvuloplasty.

01 noviembre 2011

JACC CARDIOVASCULAR INTERVENTIONS. Transfemoral Aortic Valve-in-Valve Implantation With a Balloon-Expandable Valve for the Treatment of Stentless Xenograft Severe Aortic Regurgitation

Rodrigo Bagur, MD; Josep Rodés-Cabau, MD; Robert De Larochellière, MD; Daniel Doyle, MD; Michel Rheault, MD; Éric Dumont, MD

An 80-year-old woman was admitted with pulmonary edema. She had a history of 2 prior sternotomies: a coronary artery bypass grafting (CABG) plus aortic valve replacement (AVR) with a 23-mm Medtronic-Freestyle (Minneapolis, Minnesota) stentless bioprosthesis 15 years ago, and a redo CABG 10 years ago. Doppler echocardiography showed severe aortic xenograft regurgitation ((Figure 1)A and (Figure 1)B, Online Videos 1, 2, and 3). The patient was considered at very high risk for re-AVR (third sternotomy, STS score: 10.7%, logistical EuroSCORE: 26.3%) and was consequently proposed for transcatheter aortic valve implantation (TAVI), therefore, a valve-in-valve procedure. J Am Coll Cardiol Intv. 2011;4(11):1248-1249. doi:10.1016/j.jcin.2011.09.006. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

05 octubre 2012

JACC. Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Non–ST-Segment Elevation Myocardial Infarction Patients

Dirk Sibbing, MD; Isabell Bernlochner, MD; Stefanie Schulz, MD; Steffen Massberg, MD; Albert Schömig, MD; Julinda Mehilli, MD; Adnan Kastrati, MD

Objectives The ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy aimed to determine the relevance of high on-clopidogrel treatment platelet reactivity (HPR) in non–ST-segment elevation myocardial infarction patients that received abciximab with unfractionated heparin (UFH) or bivalirudin during percutaneous coronary intervention (PCI). J Am Coll Cardiol. 2012;60(5):369-377. doi:10.1016/j.jacc.2012.02.044. Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

26 octubre 2012

BioVentrix launches Revivent Myocardial Anchoring System at EACTS annual meeting

Cardiovascular NEWS

BioVentrix will be launching the Revivent Myocardial Anchoring system for use in less invasive ventricular enhancement (LIVE) procedures at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS, Barcelona, Spain, 27–31 October). The Revivent system is intended for patients suffering from ischaemic cardiomyopathy.

05 junio 2012

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Predictors and Prognostic Value of Myocardial Injury During Transcatheter Aortic Valve Implantation

Ze Yie Yong, MD, Esther M. A. Wiegerinck, MD, Kirsten Boerlage-van Dijk, MD, Karel T. Koch, MD, PhD, Marije M. Vis, MD, Berto J. Bouma, MD, PhD, José P. S. Henriques, MD, PhD, Riccardo Cocchieri, MD, Jan J. Piek, MD, PhD, Bas A. J. M. de Mol, MD, PhD and Jan Baan Jr, MD, PhD

Background—Myocardial injury is a common complication during cardiac surgery and percutaneous coronary intervention and is associated with postprocedural cardiovascular morbidity and mortality. Limited data have been reported about the occurrence of myocardial damage associated with transcatheter aortic valve implantation (TAVI). Therefore, our purpose was to investigate the incidence, predictors, and prognostic value of myocardial injury during TAVI. Circulation: Cardiovascular Interventions. 2012; 5: 415-423 Published online before print June 5, 2012, doi: 10.1161/​CIRCINTERVENTIONS.111.964882. Copyright © 2012 American Heart Association, Inc. All rights reserved.

01 octubre 2011

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Percutaneous Closure of Left Ventricular Pseudoaneurysm

Yuriy Dudiy, MD, Vladimir Jelnin, MD, Bryce N. Einhorn, Itzhak Kronzon, MD, Howard A. Cohen, MD and Carlos E. Ruiz, MD, PhD

Background—Left ventricular pseudoaneurysm is a rare but serious complication from myocardial infarction and cardiac surgery. Although standard treatment is surgical intervention, percutaneous closure of left ventricular pseudoaneurysm has become an option for high-risk surgical candidates. Experience with percutaneous treatment is limited to a few single case reports. This is the first series of percutaneous treatment of the left ventricular pseudoaneurysms. Circulation: Cardiovascular Interventions. 2011; 4: 322-326 Published online before print July 26, 2011, doi: 10.1161/​CIRCINTERVENTIONS.111.962464. Copyright © 2011 American Heart Association, Inc.

09 octubre 2012

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment

Gjin Ndrepepa, MD, Franz-Josef Neumann, MD, Efthymios N. Deliargyris, MD, Roxana Mehran, MD, Julinda Mehilli, MD, Miroslaw Ferenc, MD, Stefanie Schulz, MD, Albert Schömig, MD, Adnan Kastrati, MD and Gregg W. Stone, MD

Background—The optimal antithrombotic therapy for patients with non–ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention is not well defined. We investigated the efficacy and safety of bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) in patients with non–ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment. Circulation: Cardiovascular Interventions. 2012; 5: 705-712 Published online before print October 9, 2012, doi: 10.1161/​CIRCINTERVENTIONS.112.972869. Copyright © 2012 American Heart Association, Inc. All rights reserved.

09 octubre 2012

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study

John A. Ormiston, MBChB, Patrick W. Serruys, MD, PhD, Yoshinobu Onuma, MD, Robert-Jan van Geuns, MD, PhD, Bernard de Bruyne, MD, PhD, Dariusz Dudek, MD, Leif Thuesen, MD, Pieter C. Smits, MD, PhD, Bernard Chevalier, MD, Dougal McClean, MBChB, Jacques Koolen, MD, PhD, Stephan Windecker, MD, Robert Whitbourn, MBBS, Ian Meredith, MBBS, PhD, Cecile Dorange, MSc, Susan Veldhof, RN, Karine Miquel Hebert, PhD, Richard Rapoza, PhD and Hector M. Garcia-Garcia, MD, PhD

Background—Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Circulation: Cardiovascular Interventions. 2012; 5: 620-632 Published online before print October 9, 2012, doi: 10.1161/​CIRCINTERVENTIONS.112.971549. Copyright © 2012 American Heart Association, Inc. All rights reserved.

10 junio 2012

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?

Juan M. Ruiz-Nodar, MD, PhD, Francisco Marín, MD, PhD, Vanessa Roldán, MD, PhD, José Valencia, MD, PhD, Sergio Manzano-Fernández, MD, PhD, Luis Caballero, MD, José A. Hurtado, MD, Francisco Sogorb, MD, PhD, Mariano Valdés, MD, PhD and Gregory Y.H. Lip, MD, FACC, FESC

Background—Recent European guidelines for the management of atrial fibrillation recommend oral anticoagulation (OAC) in patients with CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years, diabetes, history of previous stroke, vascular disease, age 65–74 years, and sex category [female]) ≥1. The HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly [>65 years], Drugs/alcohol concomitantly) has been suggested to assess bleeding risk in patients with atrial fibrillation (score ≥3 indicates high risk of bleeding). Despite the guidelines, this approach has never been tested in a cohort of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation. Interventions. 2012; 5: 459-466 Published online before print July 10, 2012, doi: 10.1161/​CIRCINTERVENTIONS.112.968792. Copyright © 2012 American Heart Association, Inc.